BIOMARKER:

ER positive

A1 | Sensitive

A2 | Sensitive

B | Sensitive

C1 | Sensitive

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

D | Sensitive

A1 | Resistant

A2 | Resistant

B | Resistant

C1 | Resistant

C2 | Resistant

C3 | Resistant

C4 | Resistant

D | Resistant

HER2 Negative Breast Cancer

Estrogen Receptor Positive Breast Cancer

HER2 Positive Breast Cancer

Uterine Corpus Leiomyosarcoma

Endometrial Cancer

Ovarian Cancer

Male Breast Cancer

Endometrial Adenocarcinoma

Breast Cancer

Uterine Cancer

Hormone Receptor Positive Breast Cancer

Gastric Cancer

Triple Negative Breast Cancer

CDK4 inhibitor + CDK6 inhibitor

ER positive|HER2 Negative Breast Cancer|CDK4 inhibitor + CDK6 inhibitor

ER positive|Estrogen Receptor Positive Breast Cancer|CDK4 inhibitor + CDK6 inhibitor

ER positive|Endometrial Cancer|CDK4 inhibitor + CDK6 inhibitor

ER positive|Ovarian Cancer|CDK4 inhibitor + CDK6 inhibitor

VEX

ER positive|HER2 Negative Breast Cancer|VEX

HER2 inhibitor

ER positive|HER2 Negative Breast Cancer|HER2 inhibitor

EC-P

ER positive|HER2 Negative Breast Cancer|EC-P

Aromatase inhibitor

ER positive|HER2 Negative Breast Cancer|Aromatase inhibitor

ER positive|Uterine Corpus Leiomyosarcoma|Aromatase inhibitor

ER positive|HER2 Positive Breast Cancer|AC

Selective estrogen receptor degrader

ER positive|HER2 Positive Breast Cancer|Selective estrogen receptor degrader

ribociclib

ER positive|HER2 Negative Breast Cancer|ribociclib

ER positive|Estrogen Receptor Positive Breast Cancer|ribociclib

ER positive|Endometrial Cancer|ribociclib

ER positive|Ovarian Cancer|ribociclib

tamoxifen

ER positive|Estrogen Receptor Positive Breast Cancer|tamoxifen

ER positive|Male Breast Cancer|tamoxifen

trastuzumab + lapatinib

ER positive|HER2 Positive Breast Cancer|trastuzumab + lapatinib

ER positive|Estrogen Receptor Positive Breast Cancer|

ER positive|Uterine Corpus Leiomyosarcoma|

megestrol

ER positive|Uterine Corpus Leiomyosarcoma|megestrol

anastrozole

ER positive|HER2 Negative Breast Cancer|anastrozole

ER positive|Estrogen Receptor Positive Breast Cancer|anastrozole

ER positive|Uterine Corpus Leiomyosarcoma|anastrozole

ER positive|Uterine Cancer|anastrozole

letrozole

ER positive|HER2 Negative Breast Cancer|letrozole

ER positive|Estrogen Receptor Positive Breast Cancer|letrozole

ER positive|Endometrial Adenocarcinoma|letrozole

ER positive|Gastric Cancer|letrozole

abemaciclib + eFT226

ER positive|HER2 Negative Breast Cancer|abemaciclib + eFT226

ER positive|Estrogen Receptor Positive Breast Cancer|abemaciclib + eFT226

abemaciclib

ER positive|HER2 Negative Breast Cancer|abemaciclib

ER positive|Estrogen Receptor Positive Breast Cancer|abemaciclib

ER positive|Endometrial Cancer|abemaciclib

ER positive|Ovarian Cancer|abemaciclib

ER positive|Endometrial Adenocarcinoma|abemaciclib

Immunotherapy + fulvestrant

ER positive|Estrogen Receptor Positive Breast Cancer|Immunotherapy + fulvestrant

fulvestrant

ER positive|HER2 Negative Breast Cancer|fulvestrant

ER positive|Estrogen Receptor Positive Breast Cancer|fulvestrant

ER positive|HER2 Positive Breast Cancer|fulvestrant

cyclophosphamide + thiotepa

ER positive|HER2 Negative Breast Cancer|cyclophosphamide + thiotepa

CFI-402257

ER positive|HER2 Negative Breast Cancer|CFI-402257

gimeracil/oteracil/tegafur

ER positive|HER2 Negative Breast Cancer|gimeracil/oteracil/tegafur

ARV-471

ER positive|HER2 Negative Breast Cancer|ARV-471

OP-1250

ER positive|HER2 Negative Breast Cancer|OP-1250

ER positive|Estrogen Receptor Positive Breast Cancer|OP-1250

exemestane

ER positive|HER2 Negative Breast Cancer|exemestane

ER positive|Estrogen Receptor Positive Breast Cancer|exemestane

palbociclib

ER positive|HER2 Negative Breast Cancer|palbociclib

ER positive|Estrogen Receptor Positive Breast Cancer|palbociclib

palbociclib + PF-05212384

ER positive|HER2 Negative Breast Cancer|palbociclib + PF-05212384

ER positive|Estrogen Receptor Positive Breast Cancer|palbociclib + PF-05212384

trastuzumab + pertuzumab

ER positive|Estrogen Receptor Positive Breast Cancer|trastuzumab + pertuzumab

ER positive|HER2 Positive Breast Cancer|trastuzumab + pertuzumab

trastuzumab

ER positive|HER2 Negative Breast Cancer|trastuzumab

ER positive|HER2 Positive Breast Cancer|trastuzumab

bevacizumab

ER positive|HER2 Negative Breast Cancer|bevacizumab

ER positive|Estrogen Receptor Positive Breast Cancer|bevacizumab

elacestrant

ER positive|HER2 Negative Breast Cancer|elacestrant

ER positive|Estrogen Receptor Positive Breast Cancer|elacestrant

capecitabine

ER positive|HER2 Negative Breast Cancer|capecitabine

ER positive|Breast Cancer|capecitabine

HER2 inhibitor + OP-1250

ER positive|HER2 Positive Breast Cancer|HER2 inhibitor + OP-1250

palbociclib + OP-1250

ER positive|HER2 Negative Breast Cancer|palbociclib + OP-1250

palbociclib + ARV-471

ER positive|HER2 Negative Breast Cancer|palbociclib + ARV-471

D-0502

ER positive|HER2 Negative Breast Cancer|D-0502

abemaciclib + copanlisib

ER positive|HER2 Negative Breast Cancer|abemaciclib + copanlisib

methotrexate

ER positive|HER2 Negative Breast Cancer|methotrexate

abemaciclib + LY3484356

ER positive|HER2 Negative Breast Cancer|abemaciclib + LY3484356

toremifene

ER positive|Estrogen Receptor Positive Breast Cancer|toremifene

neratinib

ER positive|HER2 Positive Breast Cancer|neratinib

GDC-0032

ER positive|HER2 Negative Breast Cancer|GDC-0032

pembrolizumab

ER positive|HER2 Negative Breast Cancer|pembrolizumab

Z-endoxifen hydrochloride

ER positive|Estrogen Receptor Positive Breast Cancer|Z-endoxifen hydrochloride

SAR439859

ER positive|Estrogen Receptor Positive Breast Cancer|SAR439859

ZN-c5

ER positive|HER2 Negative Breast Cancer|ZN-c5

CB-228

ER positive|HER2 Negative Breast Cancer|CB-228

H3B-6545

ER positive|HER2 Negative Breast Cancer|H3B-6545

alpelisib

ER positive|Estrogen Receptor Positive Breast Cancer|alpelisib

AZD9833

ER positive|HER2 Negative Breast Cancer|AZD9833

venetoclax

ER positive|HER2 Negative Breast Cancer|venetoclax

ER positive|Estrogen Receptor Positive Breast Cancer|venetoclax

everolimus

ER positive|HER2 Negative Breast Cancer|everolimus

RG4733

ER positive|Estrogen Receptor Positive Breast Cancer|RG4733

lenvatinib

ER positive|HER2 Negative Breast Cancer|lenvatinib

entinostat

ER positive|Estrogen Receptor Positive Breast Cancer|entinostat

tamoxifen + goserelin acetate

ER positive|Estrogen Receptor Positive Breast Cancer|tamoxifen + goserelin acetate

dalpiciclib

ER positive|HER2 Negative Breast Cancer|dalpiciclib

pyrotinib + dalpiciclib

ER positive|HER2 Positive Breast Cancer|pyrotinib + dalpiciclib

PF-07248144

ER positive|HER2 Negative Breast Cancer|PF-07248144

GDC-0927

ER positive|HER2 Negative Breast Cancer|GDC-0927

GDC-9545

ER positive|HER2 Negative Breast Cancer|GDC-9545

rivoceranib

ER positive|HER2 Negative Breast Cancer|rivoceranib

RG7440

ER positive|HER2 Negative Breast Cancer|RG7440

Hemay022

ER positive|HER2 Positive Breast Cancer|Hemay022

SCR-6852

ER positive|HER2 Negative Breast Cancer|SCR-6852

ER positive|Estrogen Receptor Positive Breast Cancer|SCR-6852

TQB3616

ER positive|HER2 Negative Breast Cancer|TQB3616

enobosarm

ER positive|HER2 Negative Breast Cancer|enobosarm

palbociclib + letrozole

ER positive|Endometrial Cancer|palbociclib + letrozole

G1T48

ER positive|HER2 Negative Breast Cancer|G1T48

tamoxifen + CB-228

ER positive|Estrogen Receptor Positive Breast Cancer|tamoxifen + CB-228

trastuzumab + palbociclib

ER positive|HER2 Positive Breast Cancer|trastuzumab + palbociclib

tamoxifen + GDC-0032

ER positive|Estrogen Receptor Positive Breast Cancer|tamoxifen + GDC-0032

lapatinib + ado-trastuzumab emtansine

ER positive|HER2 Positive Breast Cancer|lapatinib + ado-trastuzumab emtansine

ixazomib

ER positive|Estrogen Receptor Positive Breast Cancer|ixazomib

ponatinib

ER positive|Estrogen Receptor Positive Breast Cancer|ponatinib

MLN8237

ER positive|Estrogen Receptor Positive Breast Cancer|MLN8237

pertuzumab + ado-trastuzumab emtansine

ER positive|Hormone Receptor Positive Breast Cancer|pertuzumab + ado-trastuzumab emtansine

LY3484356

ER positive|HER2 Negative Breast Cancer|LY3484356

ER positive|Estrogen Receptor Positive Breast Cancer|LY3484356

sunitinib

ER positive|Estrogen Receptor Positive Breast Cancer|sunitinib

EP0062

ER positive|HER2 Negative Breast Cancer|EP0062

docetaxel + epirubicin

ER positive|HER2 Negative Breast Cancer|docetaxel + epirubicin

pyrotinib + letrozole

ER positive|Estrogen Receptor Positive Breast Cancer|pyrotinib + letrozole

palbociclib + SAR439859

ER positive|HER2 Negative Breast Cancer|palbociclib + SAR439859

ER positive|Estrogen Receptor Positive Breast Cancer|palbociclib + SAR439859

palbociclib + H3B-6545

ER positive|HER2 Negative Breast Cancer|palbociclib + H3B-6545

anlotinib

ER positive|Ovarian Cancer|anlotinib

capivasertib

ER positive|HER2 Negative Breast Cancer|capivasertib

ABSK091

ER positive|Estrogen Receptor Positive Breast Cancer|ABSK091

GDC-0941

ER positive|HER2 Negative Breast Cancer|GDC-0941

ruxolitinib

ER positive|Estrogen Receptor Positive Breast Cancer|ruxolitinib

enzalutamide capsule + fulvestrant

ER positive|HER2 Negative Breast Cancer|enzalutamide capsule + fulvestrant

INT230-6

ER positive|Estrogen Receptor Positive Breast Cancer|INT230-6

LX-039

ER positive|HER2 Negative Breast Cancer|LX-039

HRS8807

ER positive|HER2 Negative Breast Cancer|HRS8807

everolimus + LY3484356

ER positive|HER2 Negative Breast Cancer|everolimus + LY3484356

alpelisib + LY3484356

ER positive|HER2 Negative Breast Cancer|alpelisib + LY3484356

letrozole + SAR439859

ER positive|HER2 Negative Breast Cancer|letrozole + SAR439859

capivasertib + AZD9833

ER positive|HER2 Negative Breast Cancer|capivasertib + AZD9833

CR 1477

ER positive|HER2 Negative Breast Cancer|CR 1477

RGT-419B

ER positive|Estrogen Receptor Positive Breast Cancer|RGT-419B

ZEN-3694

ER positive|HER2 Negative Breast Cancer|ZEN-3694

ER positive|Estrogen Receptor Positive Breast Cancer|ZEN-3694

MLN4924

ER positive|Estrogen Receptor Positive Breast Cancer|MLN4924

palbociclib + CGM097

ER positive|Estrogen Receptor Positive Breast Cancer|palbociclib + CGM097

CGM097

ER positive|Estrogen Receptor Positive Breast Cancer|CGM097

levo-tetrahydropalmatine

ER positive|Estrogen Receptor Positive Breast Cancer|levo-tetrahydropalmatine

MK-2206 + D9

ER positive|Estrogen Receptor Positive Breast Cancer|MK-2206 + D9

SNG-162

ER positive|Estrogen Receptor Positive Breast Cancer|SNG-162

palbociclib + CR-1-31-B

ER positive|Estrogen Receptor Positive Breast Cancer|palbociclib + CR-1-31-B

darolutamide

ER positive|Estrogen Receptor Positive Breast Cancer|darolutamide

enzalutamide capsule

ER positive|Estrogen Receptor Positive Breast Cancer|enzalutamide capsule

palbociclib + ZEN-3694

ER positive|Estrogen Receptor Positive Breast Cancer|palbociclib + ZEN-3694

abemaciclib + ZEN-3694

ER positive|Estrogen Receptor Positive Breast Cancer|abemaciclib + ZEN-3694

palbociclib + APG-2575

ER positive|Estrogen Receptor Positive Breast Cancer|palbociclib + APG-2575

paclitaxel + eribulin mesylate

ER positive|Estrogen Receptor Positive Breast Cancer|paclitaxel + eribulin mesylate

XMT-1660

ER positive|HER2 Negative Breast Cancer|XMT-1660

everolimus + alpelisib + abemaciclib + LY3484356

ER positive|Estrogen Receptor Positive Breast Cancer|everolimus + alpelisib + abemaciclib + LY3484356

palbociclib + STX-478

ER positive|Estrogen Receptor Positive Breast Cancer|palbociclib + STX-478

Q901

ER positive|HER2 Negative Breast Cancer|Q901

E7090

ER positive|HER2 Negative Breast Cancer|E7090

SCR6106

ER positive|Estrogen Receptor Positive Breast Cancer|SCR6106

sorafenib

ER positive|Estrogen Receptor Positive Breast Cancer|sorafenib

metformin

ER positive|Estrogen Receptor Positive Breast Cancer|metformin

Aromatase inhibitor

ER positive|HER2 Negative Breast Cancer|Aromatase inhibitor

ER positive|Uterine Corpus Leiomyosarcoma|Aromatase inhibitor

S63845 + A-1331852

ER positive|Estrogen Receptor Positive Breast Cancer|S63845 + A-1331852

RG7440 + A-1331852

ER positive|Estrogen Receptor Positive Breast Cancer|RG7440 + A-1331852

doxorubicin hydrochloride + Z-endoxifen

ER positive|Estrogen Receptor Positive Breast Cancer|doxorubicin hydrochloride + Z-endoxifen

ISM5043

ER positive|HER2 Negative Breast Cancer|ISM5043

zoledronic acid

ER positive|HER2 Negative Breast Cancer|zoledronic acid

palbociclib + Senexin B

ER positive|Estrogen Receptor Positive Breast Cancer|palbociclib + Senexin B

palbociclib + SNX-631

ER positive|Estrogen Receptor Positive Breast Cancer|palbociclib + SNX-631

palbociclib + nafamostat

ER positive|Estrogen Receptor Positive Breast Cancer|palbociclib + nafamostat

nafamostat

ER positive|Estrogen Receptor Positive Breast Cancer|nafamostat

palbociclib + GZ17-6.02

ER positive|Estrogen Receptor Positive Breast Cancer|palbociclib + GZ17-6.02

lapatinib

ER positive|Estrogen Receptor Positive Breast Cancer|lapatinib

ER positive|HER2 Positive Breast Cancer|lapatinib

olaparib

ER positive|Triple Negative Breast Cancer|olaparib

SM-88

ER positive|Estrogen Receptor Positive Breast Cancer|SM-88

ZN-c3 + ZN-c5

ER positive|Estrogen Receptor Positive Breast Cancer|ZN-c3 + ZN-c5

palbociclib + ZN-c3

ER positive|Estrogen Receptor Positive Breast Cancer|palbociclib + ZN-c3

ZN-c3

ER positive|Estrogen Receptor Positive Breast Cancer|ZN-c3

PRT3645

ER positive|Estrogen Receptor Positive Breast Cancer|PRT3645

AEB071

ER positive|Estrogen Receptor Positive Breast Cancer|AEB071

ER positive|HER2 Positive Breast Cancer|AEB071

tucatinib

ER positive|HER2 Positive Breast Cancer|tucatinib

MK-8776

ER positive|Estrogen Receptor Positive Breast Cancer|MK-8776

ACR-368

ER positive|Estrogen Receptor Positive Breast Cancer|ACR-368

M6620

ER positive|Estrogen Receptor Positive Breast Cancer|M6620

LY 2603618

ER positive|Estrogen Receptor Positive Breast Cancer|LY 2603618

VT02956

ER positive|Estrogen Receptor Positive Breast Cancer|VT02956

CHIR-124

ER positive|Estrogen Receptor Positive Breast Cancer|CHIR-124

PD-407824

ER positive|Estrogen Receptor Positive Breast Cancer|PD-407824

PF-00477736

ER positive|Estrogen Receptor Positive Breast Cancer|PF-00477736

AZD-7762

ER positive|Estrogen Receptor Positive Breast Cancer|AZD-7762

MYCi975

ER positive|Estrogen Receptor Positive Breast Cancer|MYCi975

ER positive|Estrogen Receptor Positive Breast Cancer|

ER positive|Uterine Corpus Leiomyosarcoma|

DC-U4106

ER positive|Estrogen Receptor Positive Breast Cancer|DC-U4106

tamoxifen

ER positive|Estrogen Receptor Positive Breast Cancer|tamoxifen

ER positive|Male Breast Cancer|tamoxifen

TEQ103

ER positive|Estrogen Receptor Positive Breast Cancer|TEQ103

SB02024

ER positive|Estrogen Receptor Positive Breast Cancer|SB02024

BRY812

ER positive|Estrogen Receptor Positive Breast Cancer|BRY812

palbociclib + AZD4573

ER positive|Estrogen Receptor Positive Breast Cancer|palbociclib + AZD4573

apalutamide

ER positive|Estrogen Receptor Positive Breast Cancer|apalutamide

doxorubicin hydrochloride

ER positive|HER2 Positive Breast Cancer|doxorubicin hydrochloride

docetaxel

ER positive|HER2 Positive Breast Cancer|docetaxel